Megan M. J. Bauman

Megan M. J. Bauman

Auto-generated profile, based on publicly available information

Megan M. J. Bauman

Department of Neurological Surgery Washington University School of Medicine St. Louis Missouri USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2021 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
MBMegan M. J. Bauman
Megan M. J. Bauman
RNRyan M. Naylor
Ryan M. Naylor
EWEelco F. Wijdicks
Eelco F. Wijdicks

6 September 2022 in World Neurosurgery
Verified
Journal Article
Closed access
RNRyan M. Naylor
Ryan M. Naylor
KHKatharine A. Henry
Katharine A. Henry
PPPierce A. Peters
Pierce A. Peters
MBMegan M.J. Bauman
Megan M.J. Bauman
NLNikita Lakomkin
Nikita Lakomkin
JGJamie J. Van Gompel
Jamie J. Van Gompel

26 June 2022 in World Neurosurgery
Verified
Journal Article
Closed access
CRCecile Riviere-Cazaux
Cecile Riviere-Cazaux
ABArchis R. Bhandarkar
Archis R. Bhandarkar
MRMasum Rahman
Masum Rahman
CZClark Zheng
Clark Zheng
MBMegan M.J. Bauman
Megan M.J. Bauman
TBTerry C. Burns
Terry C. Burns

1 April 2025 in Epilepsia Open
Verified
Journal Article
Open access
RSRohin Singh
Rohin Singh
MBMegan M. J. Bauman
Megan M. J. Bauman
KIKarimul Islam
Karimul Islam
PKPanagiotis Kerezoudis
Panagiotis Kerezoudis
SGSanjeet S. Grewal
Sanjeet S. Grewal
KSKeith Starnes
Keith Starnes
Objective: Neuromodulation for pediatric refractory epilepsy (PRE) is preferred when the seizure onset zone is not amenable to surgical resection, due to multifocal onset or involvement of eloquent cortex. Given its rapidly evolving landscape, we describe our institutional experience with neurostimulation therapies including deep brain stimulation (DBS) of the anterior nucleus (DBS‐ANT), the centromedian nucleus (DBS‐CM), responsive neurostimulation (RNS), and chronic subthreshold stimulation (CSS) to treat PRE.Methods: A retrospective chart review was conducted to identify pediatric patients (≤18 years of age) who presented to our institution with PRE. Patients were included who had at least 1 year of follow‐up after neurostimulation was started. Patients with ≥50% seizure frequency reduction at last follow‐up compared to baseline were classified as responders.Results: A total of 35 patients (21 females) were included in the series. Nine patients underwent DBS‐ANT, 9 underwent DBS‐CM (+ ANT in 7 patients), 5 underwent RNS, and 12 underwent CSS. The median age at seizure onset and surgery was 8 and 16 years, respectively. Structural lesions were the most common etiology of epilepsy (54%). Eighteen patients had prior interventions and 13 received invasive EEG. Post‐operative complications following neurostimulation implantation were noted in three patients (9%). However, no permanent deficits were noted. Median follow‐up time was 46 months (range 13–162 months). Twenty‐three patients (59%) were responders (3/9 DBS‐ANT; 7/9 DBS‐CM; 4/5 RNS; 9/12 CSS). Further, median seizure reduction was 25% (DBS‐ANT), 89% (DBS‐CM), 87% (RNS), and 88% (CSS) across the cohort. Six patients (17%) had improved subjective neurocognitive outcomes while the other 29 had stable neurocognitive outcomes.Significance: DBS, RNS, and CSS are safe and effective options for PRE. An understanding of treatment approaches can optimize results by tailoring therapy to individual patients.Plain Language Summary: This study investigates the use of various neurostimulation therapies for treating pediatric refractory epilepsy (PRE) including deep brain stimulation (DBS), responsive neurostimulation (RNS), and chronic subthreshold stimulation (CSS). Overall, neuromodulation was found to be effective in reducing seizures in most patients, with 59% of patients showing at least a 50% reduction in seizure frequency. Additionally, the treatments were generally safe, with few complications and no instances of permanent deficits.

7 February 2023 in Neurosurgery
Verified
Journal Article
Closed access
LGLuz M. Cumba Garcia
Luz M. Cumba Garcia
SBSamantha M. Bouchal
Samantha M. Bouchal
MBMegan M. J. Bauman
Megan M. J. Bauman
IPIan F. Parney
Ian F. Parney
Extracellular vesicles (EVs) are membrane-bound particles released by all cells. Previous research has found that these microscopic vesicles contribute to intercellular signaling and communication. EVs carry a variety of cargo, including nucleic acids, proteins, metabolites, and lipids. The composition of EVs varies based on cell of origin. Therefore, EVs can serve as an important biomarker in the diagnosis and treatment of various cancers. EVs derived from glioblastoma (GBM) cells carry biomarkers, which could serve as the basis for a potential diagnostic strategy known as liquid biopsy. Multiple EV isolation techniques exist, including ultrafiltration, size exclusion chromatography, flow field-flow fractionation, sequential filtration, differential ultracentrifugation, and density-gradient ultracentrifugation. Recent and ongoing work aims to identify cellular markers to distinguish GBM-derived EVs from those released by noncancerous cells. Strategies include proteomic analysis of GBM EVs, identification of GBM-specific metabolites, and use of Food and Drug Administration-approved 5-aminolevulinic acid—an oral agent that causes fluorescence of GBM cells—to recognize GBM EVs in a patient's blood. In addition, accurately and precisely monitoring changes in EV cargo concentrations could help differentiate between pseudoprogression and GBM recurrence, thus preventing unnecessary surgical interventions.

5 June 2025 in Anatomical Sciences Education
Verified
Journal Article
Closed access
MBMegan M. J. Bauman
Megan M. J. Bauman
APAmedeo Piazza
Amedeo Piazza
FTFabio Torregrossa
Fabio Torregrossa
CPCharles Wes Price
Charles Wes Price
JMJonathan M. Morris
Jonathan M. Morris
MPMaria Peris‐Celda
Maria Peris‐Celda